SCHEMBL26923623

SCHEMBL26923623

N#Cc1cnc(C(N)=O)c(NCc2ccc(Cl)cc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ VNN1 O95497 5/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ JAK3 P52333 1/20 0.42
▸ HDAC3 O15379 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ CD38 P28907 1/20 0.41
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ CTSL P07711 3/20 0.40
▸ CTSB P07858 1/20 0.40
▸ CNR1 P21554 1/20 0.40
▸ CNR2 P34972 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ CHEK1 O14757 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26922228 0.89 RPS6KB1 (0.46) VNN1HDAC1
SCHEMBL26923148 0.88 JAK3 (0.42) VNN1ALDH1A1KDM4EHPGDJAK3
SCHEMBL26922757 0.88 RPS6KB1 (0.46) VNN1ALDH1A1KDM4EHPGDJAK3
SCHEMBL29834838 0.87 RPS6KB1 (0.50) CD38CTSLCTSB
SCHEMBL26921049 0.87 RPS6KB1 (0.50) CD38CTSLCTSB
SCHEMBL29834798 0.86 RPS6KB1 (0.48) VNN1JAK3HDAC3HDAC1HDAC2
SCHEMBL26921856 0.86 RPS6KB1 (0.48) VNN1JAK3HDAC3HDAC1HDAC2
SCHEMBL26921986 0.86 AURKA (0.51) VNN1KDM4EJAK3CD38CHEK1
SCHEMBL26921355 0.80 KDM4E (0.47) VNN1ALDH1A1KDM4EHPGDCTSL
SCHEMBL29834804 0.77 RPS6KB1 (0.55) VNN1KDM4EJAK3HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240093191-A1 COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH DUX4 OVEREXPRESSION RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) 2024-03-21 — — US disclosed
EP-4288539-A1 COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH DUX4 OVEREXPRESSION Research Institute at Nationwide Children's Hospital (US) 2023-12-13 — — EP disclosed
WO-2022169922-A1 COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH DUX4 OVEREXPRESSION RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) 2022-08-11 — — WO disclosed
Send feedback